Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
10 01 2019
10 01 2019
Historique:
received:
11
03
2018
pubmed:
1
9
2018
medline:
7
1
2020
entrez:
1
9
2018
Statut:
ppublish
Résumé
Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)-induced colitis. The main objective of this study was to characterize ICPI-induced MC by exploring the differences in risk factors, colitis treatments, endoscopic features, and clinical outcomes between cancer and noncancer patients with MC with and without exposure to ICPIs. A retrospective chart review was conducted among patients diagnosed with MC from our institutional pathology database from January 2012 to January 2018. Patients were categorized into MC in cancer patients with or without ICPI exposure and in noncancer patients. Risk factors (use of tobacco and certain medications), colitis treatments (antidiarrheals and immunosuppressants), endoscopic features (with or without mucosal abnormality), and clinical outcomes (diarrhea recurrence, hospitalization, mortality) were collected and compared among the 3 groups. Of the 65 eligible patients with MC, 15 cancer patients had exposure to ICPI, 39 cancer patients had no exposure to ICPI, and 11 had no cancer diagnosis. Among the risk factors, proton pump inhibitor was more frequently used in the ICPI-induced MC cohort (P = 0.040). Furthermore, in this population, mucosal abnormality was the most common endoscopic feature compared with normal findings in the non-ICPI-induced MC groups (P = 0.106). Patients with ICPI-induced MC required more treatments with oral and intravenous steroids and nonsteroidal immunosuppressive agents (all P < 0.001) and had a higher rate of hospitalization (P < 0.001). This study suggests that despite some similarities between MC with and without exposure to ICPIs, ICPI-induced MC has a more aggressive disease course that requires more potent immunosuppressive treatment regimens and greater need for hospitalization. 10.1093/ibd/izy240_video1izy240.video15828223597001.
Sections du résumé
Background
Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)-induced colitis. The main objective of this study was to characterize ICPI-induced MC by exploring the differences in risk factors, colitis treatments, endoscopic features, and clinical outcomes between cancer and noncancer patients with MC with and without exposure to ICPIs.
Methods
A retrospective chart review was conducted among patients diagnosed with MC from our institutional pathology database from January 2012 to January 2018. Patients were categorized into MC in cancer patients with or without ICPI exposure and in noncancer patients. Risk factors (use of tobacco and certain medications), colitis treatments (antidiarrheals and immunosuppressants), endoscopic features (with or without mucosal abnormality), and clinical outcomes (diarrhea recurrence, hospitalization, mortality) were collected and compared among the 3 groups.
Results
Of the 65 eligible patients with MC, 15 cancer patients had exposure to ICPI, 39 cancer patients had no exposure to ICPI, and 11 had no cancer diagnosis. Among the risk factors, proton pump inhibitor was more frequently used in the ICPI-induced MC cohort (P = 0.040). Furthermore, in this population, mucosal abnormality was the most common endoscopic feature compared with normal findings in the non-ICPI-induced MC groups (P = 0.106). Patients with ICPI-induced MC required more treatments with oral and intravenous steroids and nonsteroidal immunosuppressive agents (all P < 0.001) and had a higher rate of hospitalization (P < 0.001).
Conclusion
This study suggests that despite some similarities between MC with and without exposure to ICPIs, ICPI-induced MC has a more aggressive disease course that requires more potent immunosuppressive treatment regimens and greater need for hospitalization. 10.1093/ibd/izy240_video1izy240.video15828223597001.
Identifiants
pubmed: 30169584
pii: 5086584
doi: 10.1093/ibd/izy240
pmc: PMC7534361
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-393Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Inflamm Bowel Dis. 2016 Feb;22(2):450-8
pubmed: 26529562
Curr Gastroenterol Rep. 2017 Feb;19(2):8
pubmed: 28265892
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Am J Gastroenterol. 2002 Nov;97(11):2829-33
pubmed: 12425555
Melanoma Res. 2016 Jun;26(3):308-11
pubmed: 26990271
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Virchows Arch. 2018 Jan;472(1):125-133
pubmed: 29143108
Expert Opin Pharmacother. 2014 Oct;15(15):2277-9
pubmed: 25164577
Curr Opin Oncol. 2016 Jul;28(4):264-8
pubmed: 27138569
Am J Gastroenterol. 2015 Jul;110(7):1056-61
pubmed: 25916222
Am J Surg Pathol. 2017 May;41(5):643-654
pubmed: 28296676
Aliment Pharmacol Ther. 2015 Aug;42(4):406-17
pubmed: 26079306
PLoS One. 2016 Jul 29;11(7):e0160221
pubmed: 27472273
Oncotarget. 2016 Aug 30;7(35):56619-56627
pubmed: 27447748
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Ann Pharmacother. 2017 Mar;51(3):253-263
pubmed: 27733667
Curr Gastroenterol Rep. 2017 Jan;19(1):3
pubmed: 28124291
Am J Gastroenterol. 2017 Jan;112(1):78-85
pubmed: 27897155
Target Oncol. 2017 Jun;12(3):301-308
pubmed: 28540478
Am J Gastroenterol. 2015 Feb;110(2):265-76; quiz 277
pubmed: 25623658
Am J Gastroenterol. 2013 May;108(5):857-8
pubmed: 23644970
J Crohns Colitis. 2011 Dec;5(6):612-8
pubmed: 22115383